Global GERD Market 2016-2020
About GERD Drugs
Gastroesophageal reflux disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the stomach and esophagus. It occurs when acidic stomach juices, or food and fluids flow back up into the food pipe (esophagus). The backwash irritates the lining of the esophagus and causes GERD. It affects all ages from infants to older adults. The symptoms of GERD include difficulty while swallowing (dysphagia), heartburn sensation, regurgitation or acid reflux, dry cough, sore throat, and chest pain.
GERD is believed to be caused by the overuse of certain medications, such as calcium channel blockers, nitrates and antihistamines. Unhealthy lifestyle factors such as smoking, drinking, slouching, consuming caffeinated drinks, eating large meals, and sleeping immediately after eating are some other typical causes for the occurrence of GERD. Pharmaceutical agents that are used to prevent complications and reduce morbidity in patients with GERD include antacids, H2 receptor antagonists, proton pump inhibitors (PPIs), and prokinetic agents.
Technavio’s analysts forecast the global GERD drugs market to grow at a CAGR of 2.85% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global GERD drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of various drug classes used in the treatment of GERD.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global GERD Market 2016-2020
Technavio recognizes the following companies as the key players in the Global GERD Market: AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson and Takeda.
Other Prominent Vendors in the market are: Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, and Zeria Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “Awareness among individuals about GERD is increasing, and there are various therapies available for its treatment. This would increase the number of treatment-seeking patients, thus giving rise to the overall consumption of related drugs. Similarly, strategic alliances among vendors to consolidate their positions in the market are also expected to exert a positive influence on the market during the forecast period.”
According to the report, the global GERD drugs market is driven the presence of huge unmet medical need in GERD. The lack of FDA approved drugs and the usage of generics and off-label drugs are causing market share erosion of prescription products. Thus, for drug makers, this presents an opportunity to develop therapies that can give them an edge over others to grab a major share of the total GERD drugs market.
Further, the report states that the use of complementary and alternative treatments by patients is a major challenge for the global GERD drugs market.
AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson, Takeda, Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, Zeria Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook